The Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR

Timothy P. Heffron,* Chudi O. Ndubaku, Laurent Salphati, Bruno Alicke, Jonathan Cheong, Joy Drobnick, Kyle Edgar, Stephen E. Gould, Leslie B. Lee, John D. Lesnick, Cristina Lewis, Jim Nonomiya, Jodie Pang, Emile G. Plise, Steve Sideris, Jeffrey Wallin, Lan Wang, Xiaolin Zhang, Alan G. Olivero.

Supporting Information

In vitro Kinase Selectivity for 16.

Class I PI3Ks:

\[
\begin{align*}
\text{PI3K}_{\alpha} & \quad K_{\text{app}} = 2 \text{ nM} \\
\text{PI3K}_{\beta} & \quad K_{\text{app}} = 46 \text{ nM} \\
\text{PI3K}_{\delta} & \quad K_{\text{app}} = 3 \text{ nM} \\
\text{PI3K}_{\gamma} & \quad K_{\text{app}} = 10 \text{ nM} \\
mTOR & \quad K_{\text{app}} = 70 \text{ nM}
\end{align*}
\]

Panel of 229 Kinases tested at 1uM 16 (Invitrogen)

| Kinase    | %inhib. |
|-----------|---------|
| ACVR1B    | 1.1     |
| AKT1      | 0.7     |
| AKT2      | 6.1     |
| AKT3      | 5.9     |
| ALK       | 2.3     |
| Abl       | 2.0     |
| Arg       | 14.1    |
| Aurora_A | 3.2     |
| Aurora_B | -9.1    |
| Aurora_C | -2.5    |
| Axl       | 6.0     |
| B-Raf     | 7.6     |
| Blk       | 28.8    |
| Bmx       | 20.8    |
| BrSK1     | 1.6     |
| Protein                | Value |
|------------------------|-------|
| Brk                    | 5.9   |
| CDK1/cyclinB           | 3.3   |
| CDK2/cyclinA           | -2.4  |
| CDK5/p25               | 0.3   |
| CDK5/p35               | 7.5   |
| CDK7/cyclinH           | 2.4   |
| CDK9/cyclinT1          | -0.9  |
| CHK1                   | 0.6   |
| CHK2                   | 11.3  |
| CK1_alpha1             | 1.9   |
| CK1_epsilon1           | 4.8   |
| CK1_gamma1             | 6.8   |
| CK1_gamma2             | 1.4   |
| CK1_gamma3             | -0.2  |
| CK2_alpha1             | 3.2   |
| CK2_alpha2             | 2.3   |
| CLK1                   | 4.0   |
| CLK2                   | 5.3   |
| CLK3                   | 7.0   |
| CSF1R                  | 21.9  |
| CSK                    | 10.0  |
| CaMKI                  | -1.4  |
| CaMKII-beta            | 0.2   |
| CaMKII_delta           | 11.6  |
| CamKII_alpha           | 2.1   |
| CamKII_delta           | -1.4  |
| CamKIV                 | 0.2   |
| Cot                    | 28.7  |
| DAPK1                  | -1.2  |
| DCAMKL2                | 3.3   |
| DNA-PK                 | 17.7  |
| DYRK1A                 | 2.8   |
| DYRK1B                 | -2.7  |
| DYRK3                  | -10.8 |
| DYRK4                  | 4.6   |
| EGFR                   | 2.5   |
| ERK1                   | 8.6   |
| ERK2                   | 5.2   |
| EphA1                  | 7.8   |
| EphA2                  | -0.7  |
| EphA4                  | 3.0   |
| EphA5                  | 5.9   |
| EphA8                  | 6.9   |
| EphB1                  | 1.9   |
| EphB2                  | 6.6   |
| EphB3                  | -0.1  |
| EphB4                  | 4.8   |
| ErbB2                  | 8.5   |
| ErbB4                  | 7.0   |
| FAK                    | -1.9  |
| Protein | Value |
|--------|-------|
| FAK2   | 4.6   |
| FGFR1  | -6.8  |
| FGFR2  | 2.3   |
| FGFR3  | 11.5  |
| FGFR4  | 5.8   |
| Fer    | 8.9   |
| Fes    | -10.1 |
| Fgr    | 37.2  |
| Flt1   | 0.6   |
| Flt3   | 21.9  |
| Flt4   | 4.8   |
| Frk    | 8.0   |
| Fyn    | 9.0   |
| GCK    | 0.9   |
| GRK2   | -3.6  |
| GRK3   | 4.6   |
| GRK4   | -4.2  |
| GRK5   | -10.0 |
| GRK6   | 2.9   |
| GRK7   | -9.5  |
| GSK3_alpha | 2.5 |
| GSK3_beta | 1.0 |
| HIPK1  | 3.3   |
| HIPK2  | 1.6   |
| HIPK4  | 2.6   |
| Haspin | 3.8   |
| Hck    | 34.0  |
| Hyl    | 3.3   |
| IGF1R  | 4.9   |
| IKK_alpha | -3.8 |
| IKK_beta | 2.3 |
| IKK_epsilon | 2.9 |
| IRAK4  | 10.2  |
| IRR    | 11.5  |
| InsR   | 6.0   |
| Itk    | 9.6   |
| JAK1   | -1.6  |
| JAK2   | 15.2  |
| JAK3   | 8.9   |
| JNK1_alpha1 | -4.2 |
| JNK2   | 9.8   |
| JNK3   | -2.7  |
| KDR    | -3.6  |
| KHS1   | 1.5   |
| Kit    | 14.1  |
| LRRK2  | 10.1  |
| LTK    | 7.8   |
| Lck    | 38.0  |
| Lyn    | 23.3  |
| LynB   | 24.9  |
| Protein              | Value |
|---------------------|-------|
| MAPKAPK2            | 1.1   |
| MAPKAPK3            | 4.4   |
| MARK1               | 4.4   |
| MARK2               | 5.5   |
| MARK3               | 4.3   |
| MARK4               | 1.5   |
| MEK1                | -0.1  |
| MEK2                | 8.1   |
| MELK                | -10.4 |
| MLK1                | 28.9  |
| MRCK_alpha          | -4.5  |
| MSK1                | 10.9  |
| MSK2                | 0.6   |
| MSSK1               | 11.1  |
| MST1                | 5.0   |
| MST2                | -2.0  |
| MST3                | -1.3  |
| MST4                | -1.5  |
| MYLK2(skMLCK)       | 3.0   |
| Mer                 | 8.1   |
| Met                 | 6.5   |
| Mink1               | 14.3  |
| MuSK                | 12.7  |
| NEK1                | -6.4  |
| NEK2                | 20.0  |
| NEK4                | 7.8   |
| NEK6                | 13.1  |
| NEK7                | -0.3  |
| NEK9                | -2.6  |
| PAK1                | 7.0   |
| PAK2                | 3.0   |
| PAK3                | -4.5  |
| PAK4                | 15.2  |
| PAK6                | 15.3  |
| PAK7                | 18.6  |
| PASK                | -5.3  |
| PDGFR_alpha         | 9.7   |
| PDGFR_beta          | 4.8   |
| PDK1                | 13.4  |
| PDK1(direct)        | -8.8  |
| PI3KC2a             | 13.2  |
| PI3KC2b             | 42.6  |
| PI3KC3_hVPS34       | 23.6  |
| PI4Ka               | 7.0   |
| PI4Kb               | 2.8   |
| PIM1                | 9.7   |
| PIM2                | -4.4  |
| PKA                 | 8.2   |
| PKC_alpha           | 7.5   |
| PKC_beta1           | 12.5  |
| Protein       | Value |
|--------------|-------|
| PKC_beta2    | 11.9  |
| PKC_delta    | 1.7   |
| PKC_epsilon | 10.7  |
| PKC_eta      | -9.0  |
| PKC_gamma    | 23.8  |
| PKC_iota     | 6.8   |
| PKC_theta    | 5.8   |
| PKC_zeta     | 1.6   |
| PKD1         | 1.6   |
| PKD2         | 4.5   |
| PKD3         | 19.9  |
| PKG1_alpha   | -3.4  |
| PKG2         | 12.1  |
| PLK1         | 3.3   |
| PLK2         | 7.2   |
| PLK3         | -4.8  |
| PRK1         | -12.7 |
| PRKAA1       | 9.3   |
| PRKAA2       | 5.8   |
| PhK_gamma1   | 2.0   |
| PhK_gamma2   | 0.0   |
| PrKK         | 8.3   |
| RAF1(Y340D,Y341D) | 42.3  |
| ROCK1        | 1.3   |
| ROCK2        | -16.1 |
| Ret          | 13.4  |
| Ron          | 8.0   |
| Ros          | -6.7  |
| Rse          | 3.6   |
| Rsk1         | -4.6  |
| Rsk2         | 1.4   |
| Rsk3         | 4.4   |
| Rsk4         | 27.4  |
| SGK1         | 13.9  |
| SGK2         | 2.8   |
| SGK3         | -3.5  |
| SIK2         | 6.8   |
| SPHK1        | -2.8  |
| SPHK2        | -2.3  |
| SRPK1        | 5.5   |
| SRPK2        | -7.7  |
| Src          | 29.9  |
| Src_N1       | 43.6  |
| Srm          | -1.1  |
| Syk          | 42.8  |
| TAO1         | -1.3  |
| TBK1         | 4.0   |
| TSSK1        | 5.5   |
| TSSK2        | -6.8  |
| TYK2         | 8.4   |
### Table of Protein Phosphorylation Levels

| Protein      | Phosphorylation Level |
|--------------|-----------------------|
| Tie2         | 7.4                   |
| TrkA         | 7.3                   |
| TrkB         | 4.2                   |
| TrkC         | 11.7                  |
| YSK1         | -8.8                  |
| Yes          | 31.3                  |
| ZAP-70       | -0.9                  |
| eEF-2K       | 5.2                   |
| p38_alpha    | -9.4                  |
| p38_alpha(direct) | 4.3             |
| p38_beta     | 6.5                   |
| p38_delta    | 12.1                  |
| p38_gamma    | 11.9                  |
| p70S6K       | 6.0                   |

### Inhibition of pAKT and pS6 in U87 cells.

![U87MG-Luc Experiment](image)

**Characterization of Biochemical and Cellular Activity in vitro.** Enzymatic activity of PI3Kα was measured using a fluorescence polarization assay that monitors formation of the product 3,4,5-inositoltriphosphate molecule (PIP3) as it competes with fluorescently labeled PIP3 for binding to the GRP-1 pleckstrin homology domain protein. An increase in phosphatidylinositol-3-phosphate product results in a decrease in fluorescence polarization signal as the labeled fluorophore is displaced from the GRP-1 protein binding site. PI3Kα was purchased from Perkin Elmer or was expressed and purified as heterodimeric recombinant protein. Tetramethylrhodamine-labeled PIP3 (TAMRA-PIP3), di-C8-PIP2, and PIP3 detection reagents
were purchased from Echelon Biosciences. PI3Kα was assayed under initial rate conditions in the presence of 10 mM Tris (pH 7.5), 25 uM ATP, 9.75 uM PIP2, 5% glycerol, 4 mM MgCl₂, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, 2% (v/v) DMSO at a 60 ng/mL concentration of PI3Kα. After assay for 30 min at 25° C, reactions were terminated with a final concentration of 9 mM EDTA, 4.5 nM TAMRA-PIP3, and 4.2 ug/mL GRP-1 detector protein before reading fluorescence polarization on an Envision plate reader. IC₅₀’s were calculated from the fit of the dose-response curves to a 4-parameter equation. Apparent Ki values, where measured, were determined at a fixed concentration of ATP near the measured Km for ATP for PI3Kα, and were calculated by fitting of the dose-response curves to an equation for tight-binding competitive inhibition. All IC₅₀’s and apparent Ki values represent geometric means of at least three determinations. These assays generally produced results within 2-fold of the reported mean.

Human recombinant mTOR(1360-2549) was expressed and purified from insect cells and assayed using a Lanthascreen fluorescence resonance energy transfer format from Invitrogen in which phosphorylation of recombinant green fluorescent protein (GFP)-4-EBP1 is detected using a terbium-labeled antibody to phospho-threonine 37/46 of 4-EBP1. Reactions were initiated with ATP and conducted in the presence of 50 Mm Hepes (pH 7.5), 0.25 nM mTOR, 400 nM GFP-4E-BP1, 8 µM ATP, 0.01% (v/v) Tween 20, 10 mM MnCl₂, 1 mM EGTA, 1 mM dithiothreitol, and 1% (v/v) DMSO. Assays were conducted under initial rate conditions at room temperature for 30 min before terminating the reaction and detecting product in the presence of 2 nM Tb-anti-p4E-BP1 antibody and 10 mM EDTA. Dose-response curves were fit to an equation for competitive tight-binding inhibition and apparent Kᵢ’s were calculated using the determined
$K_m$ for ATP of 6.1 µM. All apparent Ki values represent geometric means of minimum of two determinations. These assays generally produced results within 2-fold of the reported mean.

Anti-proliferative cellular assays were conducted using PC3 human tumor cell lines provided by the ATCC. Cell lines were cultured in RPMI supplemented with 10% fetal bovine serum, 100 units/mL penicillin, and 100 µg/mL streptomycin, 10 mM HEPES and 2 mM Glutamine at 37°C under 5% CO$_2$. PC3 cells were seeded in 384-well plates in media at 1000 cells/well or 3000 cells/well, respectively, and incubated overnight prior to the addition of compounds to a final DMSO concentration of 0.5% v/v. PC3 cells were incubated for 3 and 4 days, respectively, prior to the addition of CellTiter-Glo® reagent (Promega) and reading of luminescence using an Analyst plate reader. For anti-proliferative assays, a cytostatic agent such as aphidicolin and a cytotoxic agent such as staurosporine were included as controls. Dose-response curves were fit to a 4-parameter equation and relative EC$_{50}$’s were calculated using Assay Explorer or Genedata software. All cellular EC$_{50}$ values represent geometric means of a minimum of at least two determinations and these assays generally produced results within 3-fold of the reported mean.

**In Vitro Transport Assays.** Madin-Darby canine kidney (MDCK) cells heterologously expressing human P-gp, human BCRP or mouse Bcrp1 and LLC-PK1 cells transfected with mouse P-gp (mdr1a) were used to determine whether compounds are substrate of these transporters. MDR1-MDCKI cells were licensed from the NCI (National Cancer Institute, Bethesda, MD) while Bcrp1-MDCKII, BCRP-MDCKII and Mdr1a-LLC-PK1 cells were obtained from the Netherlands Cancer Institute (Amsterdam, The Netherlands). For transport studies, cells were seeded on 24-well Millicell plates (Millipore, Billerica, MA) 4 days prior to use (polyethylene terephtalate membrane, 1 µM pore size) at a seeding density of $2.5 \times 10^5$ cells/mL (except for MDR1-MDCKI, $1.3 \times 10^5$ cells/mL). Compounds were tested at 5 µM in the
apical to basolateral (A-B) and basolateral to apical (B-A) directions. The compounds were dissolved in transport buffer consisting of Hank’s balanced salt solution (HBSS) with 10 mM HEPES (Invitrogen Corporation, Grand Island, NY). Lucifer Yellow (Sigma-Aldrich, St. Louis, MO) was used as the paracellular marker. Compound concentrations in the donor and receiving compartments were determined by LC-MS/MS analysis. The apparent permeability ($P_{app}$), in the apical to A-B and B-A directions, was calculated after a 2-hour incubation as:

$$P_{app} = \frac{dQ}{dt} \cdot \frac{1}{AC_0}$$

Where: $dQ/dt$ = rate of compound appearance in the receiver compartment; $A$ = Surface area of the insert; $C_0$ = Initial substrate concentration at T0.

The efflux ratio (ER) was calculated as ($P_{app, B-A}/P_{app, A-B}$).

All efflux ratios reported represent the arithmetic mean of a minimum of at least two determinations and these assays generally produced results within 50% of the reported mean.

**Determination of plasma protein and brain binding.** The extent of protein binding was determined *in vitro*, in mouse plasma (Bioreclamation, Inc., Hicksville, NY) by equilibrium dialysis using a HTDialysis 96-well block (HTDialysis® LLC; Gales Ferry, CT). The compound was added to pooled plasma from multiple animals ($n \geq 3$) at a total concentration of 10 µM. Plasma samples were equilibrated with phosphate-buffered saline (pH 7.4) at 37°C in 90% humidity and 5% CO$_2$ for 4 hours. Following dialysis, concentration of compounds in plasma and buffer were measured by LC-MS/MS. The percent unbound in plasma was determined by dividing the concentration measured in the post-dialysis buffer by that measured in the post-dialysis plasma and multiplying by 100. Incubations were performed in triplicate and coefficient of variation is not greater than 30%.
The free fraction in mouse brain was determined as described by Kalvass.² Briefly, brain tissue was homogenized in 3 volumes of phosphate-buffered saline and compound was added at a final concentration of 10 µM. Aliquots of 300 µl were dialyzed in a RED device (Thermo Scientific, Rockford, IL) against a volume of 500 µl buffer for 4 h at 37°C in an incubator at 90% humidity and 5% CO₂. Following dialysis, tissues and buffer samples were analyzed as described for the plasma protein binding studies.

**Pharmacokinetic Studies in Mice.** Twelve female CD-1 mice (Charles River Laboratories, Hollister, CA) were given an oral (PO) dose of the indicated compound in 0.5% methylcellulose/0.2% Tween 80 (MCT). Two blood samples of approximately 0.15 mL were collected from each mouse (n=3 mice per timepoint) by retro-orbital bleed or terminal cardiac puncture while the animals were anesthetized with isoflurane. Blood samples were collected in tubes containing K2EDTA as the anticoagulant, predose and at 0.083, 0.25, 0.5, 1, 3, 6, 9, and 24 h post-dose. Samples were centrifuged within 1 h of collection and plasma was collected and stored at -80°C until analysis. Total concentrations of the compound were determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS), following plasma protein precipitation with acetonitrile, and injection of the supernatant onto the column, a Varian MetaSil AQ C18 column (50 × 2 mm, 5 µm particle size). A CTC HTS PAL autosampler (LEAP Technologies, Chapel Hill, NC) linked to a Shimadzu SCL-10A controller with LC-10AD pumps (Shimadzu, Columbia MD), coupled with an AB Sciex API 4000 triple quadrupole mass spectrometer (AB Sciex, Foster City, CA) were used for the LC-MS/MS assay. The aqueous mobile phase was water with 0.1% formic acid and the organic mobile phase was acetonitrile with 0.1% formic acid. The lower and upper limits of quantitation of the assay were 0.005 µM and 10 µM, respectively. The total run time was 1.5 min and the ionization was conducted in the
positive ion mode. Where brain concentration was determined, brains were collected at 1 and 6 h post-dose from 3 different animals at each time point, rinsed with ice-cold saline, weighed and stored at -80°C until analysis. For compound quantitation, mouse brains were homogenized in 3 volumes of water. The homogenates were extracted by protein precipitation with acetonitrile. LC-MS/MS analysis was conducted as described for the plasma. Brain homogenate concentrations were converted to brain concentrations for the calculations of brain-to-plasma ratios.

**Modulation of pAKT in Brain.** Female CD-1 mice were administered a single PO dose of the indicated compound. Brains and plasma were collected at the indicated time post-dose, from 3 animals at each time point. Individual brains were split in half for PD analysis and compound concentration measurement. The samples were stored at -70°C and analyzed for total concentration. For PD analysis, cell extraction buffer (Invitrogen, Camarillo, CA) containing 10 mM Tris pH 7.4, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM NaF, 20 mM Na₄P₂O₇, 2 mM Na₃VO₄, 1% Triton X-100, 10% glycerol, 0.1% SDS, and 0.5% deoxycholate was supplemented with phosphatase, protease inhibitors (Sigma, St. Louis, MO) and 1mM PMSF and added to frozen brain biopsies. Brains were homogenized with a small pestle (Konte Glass Company, Vineland, NJ), sonicated briefly on ice, and centrifuged at 20,000 g for 20 min at 4°C. Protein concentration was determined using BCA protein assay (Pierce, Rockford, IL). Proteins were separated by electrophoresis and transferred to NuPage nitrocellulose membranes (Invitrogen, Camarillo, CA). Licor Odyssey Infrared detection system (Licor, Lincoln, NE) was used to assess and quantify protein expression. PI3K pathway markers were evaluated by immunoblotting using antibodies against pAkt^{ser473} and total Akt (Invitrogen, Camarillo, CA and
Cell Signaling, Danvers, MA). Inhibition of pAkt (%) was calculated by comparing pAkt signal with that measured in untreated mice.

**In Vivo Xenograft Studies.** All *in vivo* studies were conducted in compliance with Genentech’s Institutional Animal Care and Use Committee. PTEN-null U-87 MG/M human glioblastoma cancer cells (an in-house derivative of U-87 MG cells from American Type Culture Collection (Manassas, VA)) were cultured in RPMI 1640 media plus 1% L-glutamine with 10% fetal bovine serum (HyClone; Waltham, MA). Cells in log-phase growth were harvested and resuspended in HBSS:Matrigel (BD Biosciences; Franklin Lakes, NJ) (1:1, v:v) for injection into female NCr nude mice (Taconic Farms, Cambridge City, IN) aged 20 weeks. Animals received five million cells subcutaneously in the right lateral thorax in 0.1 mL. Mice bearing established tumors in the range of 200-500 mm$^3$ were separated into groups of equally sized tumors (n = 6-7/group) to receive escalating doses of **16**. The inhibitor was formulated once weekly in 0.5% methylcellulose and 0.2% Tween-80 at concentrations needed for target doses in a volume of 0.2 mL. All formulations were stored in a refrigerator and brought to room temperature and mixed well by vortex before oral administration by gavage once daily for 23 days. Tumor volumes were calculated from perpendicular length and width caliper measurements using the formula: Tumor Volume (mm$^3$) = 0.5 X (Length X Width$^2$). Changes in body weights are reported as a percentage change from the starting weight.

A mixed modeling approach was used to analyze the repeated measurement of tumor volumes from the same animals over time since this approach addresses both repeated measurements as well as modest dropouts before study end (Pinheiro et al. 2008). Log2(tumor volume) growth traces were fitted to each dose group with restricted cubic splines for the dose and fixed time effects. Fitting was done via a linear mixed-effects model, using the R package nlme (version
3.1-97) in R version 2.13.0 (R Development Core Team 2008; R Foundation for Statistical Computing; Vienna, Austria). Fitted tumor volumes were plotted in the natural scale in Prism (version 5.0b for Mac) (GraphPad Software; La Jolla, CA). Linear mixed-effects analysis was also employed using R to analyze the repeated measurement of body weight changes from the same animals over time.

**Chemistry**

![Chemical structure](image)

**2-(2-chloro-6-morpholino-9H-purin-8-yl)propan-2-ol (12).**

4-(2-chloro-9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-yl)morpholine\(^3\) (10, 25.0 g, 0.08 mol) was cooled to -78 °C in THF (400 mL). A solution of \(n\)-butyllithium (2.5 M in hexanes, 62 mL, 0.15 mol) was added portion-wise over 10 min. The mixture gradually turned yellow. The reaction mixture stirred at -78 °C for 15 min, then anhydrous acetone (12.5 mL, 0.17 mol) was added. The resulting reaction mixture was slowly warmed to 0 °C over a 2 hour period. The mixture was subsequently quenched with water, extracted with EtOAc and dried over MgSO\(_4\). The slurry was filtered and concentrated in vacuo to provide 2-(2-chloro-6-morpholino-9-(tetrahydro-2H-pyran-2-yl)-9H-purin-8-yl)propan-2-ol. The crude material was taken up in MeOH (530 mL) and p-toluenesulfonic acid (1.3 g, 0.008 mol) was added. The reaction mixture was heated to 50 °C for 30 min. The reaction mixture was concentrated, rinsed with excess water and filtered to dryness to provide 12 (21.6 g, 94% over 2 steps).
4-methyl-5-(4, 4, 5, 5-tetramethyl (1, 3, 2-dioxaborolan-2-yl)) pyrimidine-2-ylamine (17).

To a solution of 4-methylpyrimidine-2-ylamine (8.0 g, 0.073 mol) in chloroform (320 mL) was added N-bromosuccinimide (13.7 g, 0.077 mol). The reaction mixture was stirred in the dark for 18 hrs. LC/MS indicated the reaction was completed. The mixture was diluted with DCM, then washed with 1N NaOH aq solution and brine, dried over MgSO₄, filtered and concentrated to yield 5-bromo-4-methylpyrimidine-2-ylamin (12 g, Yield: 86%).

![Chemical structure]

4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine (18).

A mixture of 5-bromo-4-methylpyrimidine-2-ylamine (5.0 g, 26 mmol), potassium acetate (7.83 g, 79.8 mmol), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- 1,3,2-dioxaborolane (7.43 g, 29.2 mmol) in dioxane (140 mL) was stirred for 20 min under nitrogen. 1,1’-bis(diphenylphosphino)ferrocene palladium (II) chloride dichloromethane adduct (1.08 g, 1.33 mmol) was added to the reaction mixture. The reaction mixture was heated to 115 ºC for 18 h under nitrogen. Upon completion, the mixture was cooled and EtOAc was added. The resulting mixture was sonicated and filtered. Additional EtOAc was used to wash the solid. The combined organic extracts were washed with water, dried over MgSO₄, filtered and concentrated. The crude was purified by chromatography eluting with 20~100% EtOAc/hexane to yield 4.5 g of 4-methyl-5-(4,4,5,5-tetramethyl (1,3,2-dioxaborolan-2-yl))pyrimidine-2-ylamine (yield: 74%). ¹H NMR (DMSO, 400 MHz): δ 8.28 (s, 1H), 6.86 (br s, 2H), 2.35 (s, 3 H), 1.25 (s, 12 H). MS (ESI) m/e (M+H⁺) 236.15, 154.07.
2-(2-(2-amino-4-methylpyrimidin-5-yl)-9-(2-hydroxyethyl)-6-morpholino-9H-purin-8-yl)propan-2-ol (4).

2-(2-chloro-6-morpholino-9H-purin-8-yl)propan-2-ol (12, 10 g, 0.03 mol) was dissolved in DMF (20 mL). 2-Bromoethyl acetate (11.1 mL, 0.1 mol) and cesium carbonate (21.9 g, 0.07 mol) were added and the reaction mixture was heated to 50 ºC for several hours. After quenching with water, the reaction mixture was extracted with EtOAc and concentrated. The crude reaction mixture was purified by silica gel chromatography (gradient of 0-50% EtOAc in hexane). The resulting 2-(2-chloro-8-(2-hydroxypropan-2-yl)-6-morpholino-9H-purin-9-yl)ethyl acetate was treated with 4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine (18, 14.5 g, 0.07 mol) and PdCl$_2$Ph$_2$ (1.8 g, 2.5 mmol) in 1 M Na$_2$CO$_3$ (100 mL) and CH$_3$CN (100 mL). The reaction mixture was divided into 10 equal batches and each was microwaved at 300 watts, 140 ºC for 15 min. All batches were then combined and concentrated then taken up into iPrOH (20 mL) and heated to reflux. After then cooling to RT the resulting solid was filtered to provide 2-(2-(2-amino-4-methylpyrimidin-5-yl)-9-(2-hydroxyethyl)-6-morpholino-9H-purin-8-yl)propan-2-ol (4, 4.6 g, 37% over 2 steps). $^1$H NMR (400 MHz, DMSO) $\delta$ 8.82 (s, 1H), 6.79 (s, 2H), 5.66 (s, 1H), 5.02 (s, 1H), 4.57 (t, $J = 6.8$ Hz, 2H), 4.21 (s, 4H), 3.84 (d, $J = 3.6$ Hz, 2H), 3.78 – 3.66 (m, 4H), 2.65 (s, 3H), 1.62 (s, 6H). $^{13}$C NMR (100 MHz, DMSO) $\delta$ 166.71, 162.99, 160.11, 156.87, 155.62, 153.81, 153.06, 121.29, 116.09, 70.42, 66.69, 59.68, 46.57, 45.75, 30.62, 25.13. HRMS (ESI): m/z calcd: C$_{19}$H$_{27}$O$_3$N$_8$ = 415.2201; found: 415.2176.
5-(9-methyl-6-morpholino-9H-purin-2-yl)pyrimidin-2-amine (5).

2-chloro-9-methyl-6-morpholin-4-yl-9H-purine (0.20 mg, 0.79 mmol), 2-aminopyrimidine-5-boronic acid, pinacol ester (227 mg, 1.02 mmol), tetrakis(triphenylphosphine)palladium(0) (46 mg, 0.039 mmol), 1.0 M of Na₂CO₃ in water (1.5 mL), and acetonitrile (1.9 mL) were combined and the reaction mixture was heated in the microwave at 140 ºC for 15 min. The reaction mixture was concentrated in vacuo and submitted for purification via reverse phase chromatography to afford the title compound as a solid (91 mg, 37%). ¹H NMR (400 MHz, DMSO) δ 9.12 (s, 2H), 8.11 (s, 1H), 7.03 (s, 2H), 3.77 (s, 3H), 3.76 – 3.73 (m, 4H), 3.32 (s, 4H).

¹³C NMR (100 MHz, DMSO) δ 164.39, 158.22, 155.20, 153.42, 152.27, 141.15, 120.89, 118.25, 66.71, 45.63, 29.85.

HRMS (ESI): m/z calcd: C₁₄H₁₇ON₈ = 313.1520; found: 313.1500.

4-(2-chloro-8-iodo-9-methyl-9H-purin-6-yl)morpholine (19).

A suspension of 2-chloro-9-methyl-6-morpholin-4-yl-9H-purine (2.95 g, 11.7 mmol) and TMEDA (2.6 mL, 2.03 g, 17.5 mmol) in THF (80 mL) was cooled to –78 ºC before the drop wise addition of n-BuLi (9.8 mL, 24.5 mmol, 2.5 M solution in hexanes). The resulting mixture was warmed to –40 ºC and stirred 40 mins. The mixture was cooled back to –78 ºC before the addition of 1-chloro-2-iodoethane (3.7 mL, 7.8 g, 40.8 mmol). The resulting mixture was allowed to warm to r.t. over a 2 h period then quenched with NH₄Cl and extracted with EtOAc.
The combined organics were dried (Na$_2$SO$_4$) and concentrated in vacuo affording the title compound as a yellow solid (4.02 g, 91%). LCMS: $R_T$ 4.09 min, $m/z = 379.9$ [M+H]$^+$. 

**4-(2-chloro-8-ethyl-9-methyl-9H-purin-6-yl)morpholine (20).**

4-(2-chloro-8-iodo-9-methyl-9H-purin-6-yl)morpholine (19, 0.20 g, 0.53 mmol) and 1,1'-bis(diphenylphosphino)ferrocene palladium(II) chloride (6.5 mg, 0.008 mmol) were dissolved in 1,4-dioxane (2.634 mL). 1.0 M of diethyl zinc in hexane (1.1 mL, 1.1 mmol) was added dropwise to the reaction mixture. The reaction was stirred at 60 °C for 2.5h, then cooled to ambient temperature. MeOH was then added drop wise, and the volatiles removed in vacuo. The crude residue was diluted with 1N HCl, water, brine and EtOAc. The layers were separated and the aqueous phase was extracted into EtOAc ($\times$3), dried over Na$_2$SO$_4$, filtered and absorbed onto Celite for purification by flash column chromatography [12 g column, 0-80% EtOAc/heptanes over 18 min] to afford the title compound as a light yellow solid (106 mg, 72%).

**5-(8-ethyl-9-methyl-6-morpholino-9H-purin-2-y1)pyrimidin-2-amine (6).**

A similar coupling procedure described for the synthesis of 5-(9-methyl-6-morpholino-9H-purin-2-yl)pyrimidin-2-amine (5) above, using 20 and 2-aminopyrimidine-5-boronic acid pinacol ester, was used to generate this compound.
\( \text{H NMR (400 MHz, DMSO)} \, \delta \, 9.11 \, (s, \, 2H), \, 7.00 \, (s, \, 2H), \, 4.24 \, (s, \, 4H), \, 3.77-3.72 \, (m, \, 4H), \, 3.71-3.69 \, (m, \, 3H), \, 2.85 \, (q, \, J = 7.5 \, Hz, \, 2H), \, 1.29 \, (t, \, J = 7.5 \, Hz, \, 3H). \) \( \text{\textsuperscript{13}C NMR (100 MHz, DMSO)} \, \delta \, 164.31, \, 158.08, \, 154.31, \, 153.26, \, 153.03, \, 152.99, \, 152.68, \, 121.03, \, 117.44, \, 66.73, \, 45.65, \, 28.60, \, 20.60, \, 11.53. \) \( \text{HRMS (ESI): m/z calcd: C}_{16}H_{21}ON_8 = 341.1833; \) found: 341.1811.

\[ \begin{align*}
\text{O} \\
\text{N} \\
\text{N} \\
\text{Cl}
\end{align*} \]

4-(2-chloro-8-cyclobutyl-9-methyl-9H-purin-6-yl)morpholine (21).

4-(2-chloro-8-iodo-9-methyl-9H-purin-6-yl)morpholine (0.5 g, 1.32 mmol), potassium cyclobutyl trifluoroborate (320 mg, 1.98 mmol), \( \text{Cs}_2\text{CO}_3 \) (1.3 g, 3.95 mmol), and \( \text{Pd(OAc)}_2 \) (6 mg, 0.03 mmol) were suspended in toluene (4.8 mL) and heated at 100 °C overnight. The reaction mixture was cooled to ambient temperature and diluted with saturated aqueous sodium bicarbonate, water, brine and EtOAc. The layers were separated and the aqueous phase was extracted into EtOAc (3x), dried over \( \text{Na}_2\text{SO}_4 \), filtered and absorbed onto Celite for purification via FCC [80 g, 0–50% EtOAc/heptanes] to afford 64 mg (16%) of the title compound.

\[ \begin{align*}
\text{O} \\
\text{N} \\
\text{N} \\
\text{Cl}
\end{align*} \]

5-(8-cyclobutyl-9-methyl-6-morpholino-9H-purin-2-yl)pyrimidin-2-amine (7).

A similar coupling procedure described for the synthesis of 5-(9-methyl-6-morpholino-9H-purin-2-yl)pyrimidin-2-amine (5) above, using 21 and 2-aminopyrimidine-5-boronic acid pinacol ester, was used to generate this compound. \( \text{H NMR (400 MHz, DMSO)} \, \delta \, 9.11 \, (s, \, 2H), \, 7.00 \, (s, \, 2H), \, 4.27 \, (s, \, 4H), \, 3.90 \, – \, 3.79 \, (m, \, 1H), \, 3.79-3.71 \, (m, \, 4H), \, 3.62 \, (s, \, 3H), \, 2.43-2.34 \, (m, \, 4H), \, 2.16 \, – \, 2.01 \, (m, \, 1H), \, 1.96 \, – \, 1.85 \, (m, \, 1H). \) \( \text{\textsuperscript{13}C NMR (100 MHz, DMSO)} \, \delta \, 164.31, \, 158.09, \)
3-(2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)oxetan-3-ol (22).

To 4-(2-chloro-9-methyl-9H-purin-6-yl)morpholine (1.50 g, 5.93 mmol) in THF (48 mL) at –48 °C was added 2.5 M of n-butyllithium in hexanes (6.6 mL, 16.6 mmol) and stirred for 30 min. Following this, 3-oxetanone (1.1 mL, 23.7 mmol) was added and the reaction mixture was stirred for 2 h. The mixture was quenched with water and extracted with EtOAc. The combined organics were dried over Na₂SO₄, filtered and absorbed onto Celite for purification via FCC [80g, 0–100% EtOAc in heptanes] to afford the title compound as a white solid (1.32 g, 68%).

3-(2-(2-aminopyrimidin-5-yl)-9-methyl-6-morpholino-9H-purin-8-yl)oxetan-3-ol (8).

A similar coupling procedure described for the synthesis of 5-(9-methyl-6-morpholino-9H-purin-2-yl)pyrimidin-2-amine (5) above, using 22 and 2-aminopyrimidine-5-boronic acid pinacol ester, was used to generate this compound.

^1^H NMR (400 MHz, DMSO) δ 9.13 (d, J = 5.1 Hz, 2H), 7.05 (s, 2H), 6.90 (s, 1H), 4.97 (dd, J = 149.7, 6.8 Hz, 4H), 4.28 (s, 4H), 3.84 – 3.73 (m, 4H), 3.68 (s, 3H). ^13^C NMR (100 MHz, DMSO) δ 164.42, 164.39, 158.27, 158.23, 155.33, 155.30, 153.95, 153.91, 153.34, 153.31, 150.45,
HRMS (ESI): m/z calcd: C_{17}H_{21}O_{3}N_{8} = 385.173; found: 385.1710.

4-(2-chloro-8-(3-methoxyoxetan-3-yl)-9-methyl-9H-purin-6-yl)morpholine (23).

A solution of 3-(2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)oxetan-3-ol (0.5 g, 1.54 mmol) in DMF (8.3 mL) was cooled to 0 °C. NaH (60% dispersion in oil, 185 mg, 7.70 mmol) was added in one portion. The reaction mixture was stirred for 5 minutes and resulted in a dark orange hue. Methyl iodide (0.29 mL, 4.62 mmol) was added and the reaction mixture was allowed to warm to ambient temperature and stirred 2 h. The reaction was diluted with saturated aqueous Na_{2}CO_{3} solution and extracted into EtOAc. The combined organics were dried over Na_{2}SO_{4}, filtered and absorbed onto Celite for purification via FCC (80 g column, 0–100% EtOAc in heptane) to afford the title compound as a white solid (505 mg, 96%).

5-(8-(3-methoxyoxetan-3-yl)-9-methyl-6-morpholino-9H-purin-2-yl)pyrimidin-2-amine (9).

A similar coupling procedure described for the synthesis of 5-(9-methyl-6-morpholino-9H-purin-2-yl)pyrimidin-2-amine (5) above, using 23 and 2-aminopyrimidine-5-boronic acid pinacol ester, was used to generate this compound.

^{1}H NMR (400 MHz, DMSO) δ 9.14 (s, 2H), 7.06 (s, 2H), 5.12 (d, J = 7.1 Hz, 2H), 4.84 (d, J = 7.1 Hz, 2H), 4.29 (s, 4H), 3.80-3.74 (m, 4H), 3.64 (s, 3H), 3.04 (s, 3H). ^{13}C NMR (100 MHz,
DMSO) δ 164.48, 164.45, 158.30, 155.57, 154.00, 153.35, 147.38, 120.75, 116.98, 77.74, 77.27, 66.71, 52.28, 29.43. HRMS (ESI): m/z calcd: C_{18}H_{23}O_{3}N_{8} = 399.1888; found: 399.1866.

5-(6,6-dimethyl-4-morpholino-8,9-dihydro-6H-[1,4]oxazino[4,3-e]purin-2-yl)-4-methylpyrimidin-2-amine (15).

A mixture of 2-(2-(2-amino-4-methylpyrimidin-5-yl)-9-(2-hydroxyethyl)-6-morpholino-9H-purin-8-yl)propan-2-ol (4, 550 mg, 1.3 mmol) and TFA (0.36 mL, 4.7 mmol) in toluene (9 mL) was heated at 110 ºC and stirred 4 h. The reaction mixture was cooled to room temperature and concentrated in vacuo. Analytical LC-MS indicated conversion to the cyclic product as well as the E2 by-product, 2-(2-(2-amino-4-methylpyrimidin-5-yl)-6-morpholino-8-(prop-1-en-2-yl)-9H-purin-9-yl)ethanol. The crude residue was dissolved in DMF (1 mL) and purified by preparative rp-HPLC. This provided 302 mg (57% yield) of 15. \(^1\)H NMR (400 MHz, DMSO) δ 8.79 (s, 1H), 6.79 (s, 2H), 4.27 (d, J = 53.4 Hz, 4H), 4.12 (s, 5H), 3.81 – 3.66 (m, 5H), 2.71 – 2.58 (m, 3H), 1.58 (s, 6H). \(^13\)C NMR (100 MHz, DMSO) δ 166.70, 162.98, 159.99, 156.87, 152.93, 151.73, 121.19, 117.21, 74.17, 66.66, 58.28, 45.76, 41.93, 27.81, 25.01. HRMS (ESI): m/z calcd: C_{19}H_{25}O_{2}N_{8} = 397.2095; found: 397.2074.

2-chloro-6,6-dimethyl-4-morpholino-8,9-dihydro-6H-[1,4]oxazino[4,3-e]purine (13)

2-(2-chloro-6-morpholino-9H-purin-8-yl)propan-2-ol (12, ca. 15.0 g, 50.4 mmol) was treated with 1,2-dibromoethane (8.7 mL, 100 mmol) and cesium carbonate (41.0 g, 126 mmol) in DMF
(200 mL). The reaction mixture was heated at 90 °C for 1.5 h. LC-MS indicated complete conversion to the cyclic product with ~10% of E2 elimination product present. The reaction mixture was cooled to room temperature and poured into a separatory funnel containing 1 N HCl and EtOAc (50:50). The aqueous layer was extracted several times with EtOAc and the combined organic portions were washed once with water. Subsequent drying over MgSO₄ was followed by filtration and concentration to yield a crude oily residue. This material was loaded onto a 300 g ISCO column and purified by slow gradient flash column chromatography (15-30% EtOAc in heptane). Fractions containing the desired product were concentrated and dried down under high vacuum pressure for an overnight period to give 14.3 g (88% yield) of 2-chloro-6,6-dimethyl-4-morpholino-8,9-dihydro-6H-[1,4]oxazino[3,4-e]purine (13). MS (ESI+): m/z 324.2 (M+H⁺). ¹H NMR (400 MHz, DMSO) δ 4.07 (m, 8H), 3.72 (m, 4H), 1.57 (s, 6H).

5-(6,6-dimethyl-4-morpholino-8,9-dihydro-6H-[1,4]oxazino[3,4-e]purin-2-yl)pyrimidin-2-amine (16).

2-Chloro-6,6-dimethyl-4-morpholino-8,9-dihydro-6H-[1,4]oxazino[3,4-e]purine (180 mg, 0.56 mmol) in 1,2-dimethoxyethane (5.1 mL) was added 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine (180 mg, 0.83 mmol) and 1.0 M of cesium carbonate in water (1.7 mL). The reaction mixture was degassed for 5 min and recycled with nitrogen atmosphere. Subsequently, 1,1'-bis(diphenylphosphino)ferrocene palladium(II) chloride (54 mg, 0.067 mmol) was added, and the mixture was degassed and recycled again. The reaction vial was then subjected to microwave irradiation for 20 mins at 140 °C. Solid precipitate that formed during the reaction was filtered and rinsed with excess water. The precipitate was taken up in DCM and purified by FCC (40 g column, 0.5-4% MeOH in DCM, slow gradient) to isolate 16 as a tan-colored solid (56 mg, 27% yield). ¹H NMR (400 MHz, DMSO) δ 9.10 (s, 2H), 7.03 (s, 2H), 4.23 (s, 4H), 4.17 – 4.02 (m, 4H), 3.86 – 3.68 (m, 4H), 1.58 (s, 6H). ¹³C NMR (100 MHz, DMSO) δ
HRMS (ESI): m/z calcd: C_{18}H_{23}O_{2}N_{8} = 383.1938; found: 383.1914.

1 Experimental details for the Class I PI3K assays used were identical to that previously reported: Heffron, T. P.; Heald, R.; Ndubaku, C.; Wei, B. Q.; Augistin, M.; Do, S.; Edgar, K.; Eigenbrot, C.; Friedman, L.; Gancia, E.; Jackson, P. S.; Jones, G.; Kolesnikov, A.; Lee, L. B.; Lesnick, J. D.; Lewis, C.; McLean, N.; Mörtle, M.; Nonomiya, J.; Pang, J.; Price, S.; Prior, W. W.; Salphati, L.; Sideris, S.; Staben, S. T.; Steinbacher, S.; Tsui, V.; Wallin, J.; Sampath, D.; Olivero, A. G.; “The Rational Design of Selective Inhibitors of Phosphoinositide 3-Kinase Culminating in the Identification of Clinical Candidate GDC-0326.” J. Med. Chem. 2016, ASAP, DOI: 10.1021/acs.jmedchem.5b01483

2 Kalvass, J. C.; Maurer, T. S.; Pollack, G. M. Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios. Drug Metab. Dispos. 2007, 35, 660-666.

3 Murray, J. M.; Sweeney, Z. K.; Chan, B. K.; Balazs, M.; Bradley, E.; Castanedo, G.; Chabot, C.; Chantry, D.; Flagella, M.; Goldstein, D. M.; Kondru, R.; Lesnick, J.; Li, J.; Lucas, M. C.; Nonomiya, J.; Pang, J.; Price, S.; Salphati, L.; Safina, B.; Savy, P. P. A.; Seward, E. M.; Ultsch, M.; Sutherlin, D. P. Potent and Highly Selective Benzimidazole Inhibitors of PI3-Kinase Delta. J. Med. Chem. 2012, 55, 7686-7695.